2024-03-13 10:01:09 ET
Silence Therapeutics plc (SLN)
Q4 2023 Earnings Conference
March 13, 2024 08:00 AM ET
Company Participants
Gem Hopkins - Head of Investor Relations & Corporate Communications
Craig Tooman - President & Chief Executive Officer
Rhonda Hellums - Chief Financial Officer
Steven Romano - Head of R&D
Conference Call Participants
Mike Ulz - Morgan Stanley
Kostas Biliouris - BMO Capital Markets
Patrick Trucchio - H.C. Wainwright
Keay Nakae - Chardan Research
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Silence Therapeutics 2023 Full Year Results Webcast and Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your first speaker today, Gem Hopkins. Please go ahead.
Gem Hopkins
Good morning and good afternoon, everyone. Thank you for joining us today. My name is Gem Hopkins, Vice President of Investor Relations and Corporate Communications at Silence. Joining me on today's call are Craig Tooman, our President and CEO, who will provide an update on the business; Rhonda Hellums, our Chief Financial Officer, who will review our financial performance; and Steven Romano, our Head of R&D, who will provide an update on our clinical programs. For those of you participating via conference call, the accompanying slides can be accessed by going to the Investors section of our corporate website at www.silence-therapeutics.com.
Turning to Slide 2, I'd like to remind you that during today's call, management will make projections or other forward-looking statements regarding anticipated future events or the future financial performance of the company, including clinical development, timing and objectives, the therapeutic potential of our product candidates, our operational plans and strategies, anticipated milestone payments, anticipated operating and capital expenditures, business prospects and projected cash runway. Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed in our most recent annual report on file with the SEC....
Read the full article on Seeking Alpha
For further details see:
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript